Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/12283
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Anderson, Nigel J | - |
dc.contributor.author | Wada, Morikatsu | - |
dc.contributor.author | Schneider-Kolsky, Michal | - |
dc.contributor.author | Rolfo, Maureen | - |
dc.contributor.author | Joon, Daryl Lim | - |
dc.contributor.author | Khoo, Vincent | - |
dc.date.accessioned | 2015-05-16T01:56:43Z | |
dc.date.available | 2015-05-16T01:56:43Z | |
dc.date.issued | 2014-07-01 | - |
dc.identifier.citation | Acta Oncologica (stockholm, Sweden) 2014; 53(10): 1305-11 | en_US |
dc.identifier.other | PUBMED | en |
dc.identifier.uri | https://ahro.austin.org.au/austinjspui/handle/1/12283 | en |
dc.description.abstract | To determine the validity of QUANTEC recommendations in predicting acute dysphagia using intensity-modulated head and neck radiotherapy.Seventy-six consecutive patients with locally advanced squamous cell carcinoma (SCC) of the head and neck +/- systemic therapy were analyzed. Multiple dose parameters for the larynx (V50Gy, Dmean and Dmax) were recorded. Acute dysphagia toxicity was prospectively scored in all treatment weeks (week 1-6 or 1-7) using CTCAEv3 by three blinded investigators. QUANTEC larynx recommendations (V50Gy < 27%, Dmean < 44 Gy, Dmean < 40 Gy, Dmax < 66 Gy) were used to group the cohort (i.e. V50Gy < 27% vs. V50Gy > 27%). The proportion of patients with Grade 3 dysphagia was compared within each group.There was a significant reduction in the incidence of grade 3 toxicity in the V50Gy < or > 27% group at week 5 (14.3% vs. 45.2%, p = 0.01) and 6 (25.9% vs. 65.9%, p < 0.01). A significant reduction at week 5 (14.7% vs. 50.0, p = 0.02) and 6 (32.4% vs. 67.6%, p = 0.01) was seen in Dmean < 44 Gy when compared to Dmean > 44 Gy. Dmean < 40 Gy also delivered a significant reduction at week 5 (5.6% vs. 42.3%, p < 0.01) and week 6 (23.5% vs. 59.3%, p = 0.01). A significant toxicity reduction at treatment week 6 (28.0% vs. 63.0%, p = 0 < 01) was seen from Dmax < 66 Gy to Dmax > 66 Gy. V50Gy > 27% (p < 0.01), Dmean > 40 Gy (p = 0.01) and Dmax > 66 Gy (p < 0.01) were also predictors of Grade 3 dysphagia when analyzed with multiple clinical risk factors.QUANTEC late toxicity recommendations for dose to larynx during IMRT are a useful predictor for acute dysphagia toxicity in this patient cohort. Furthermore, this included chemoradiotherapy regimes and post-operative radiotherapy patients, allowing for prophylactic implementation of supportive care measures. | en_US |
dc.language.iso | en | en |
dc.subject.other | Carcinoma, Squamous Cell.radiotherapy | en |
dc.subject.other | Deglutition Disorders.classification.epidemiology.etiology | en |
dc.subject.other | Female | en |
dc.subject.other | Head and Neck Neoplasms.radiotherapy | en |
dc.subject.other | Humans | en |
dc.subject.other | Incidence | en |
dc.subject.other | Larynx.radiation effects | en |
dc.subject.other | Male | en |
dc.subject.other | Middle Aged | en |
dc.subject.other | Organs at Risk.radiation effects | en |
dc.subject.other | Radiotherapy, Intensity-Modulated.adverse effects.methods | en |
dc.subject.other | Stomatitis.complications | en |
dc.title | Dose-volume response in acute dysphagia toxicity: Validating QUANTEC recommendations into clinical practice for head and neck radiotherapy. | en_US |
dc.type | Journal Article | en_US |
dc.identifier.journaltitle | Acta Oncologica (Stockholm, Sweden) | en_US |
dc.identifier.affiliation | Radiation Oncology | en_US |
dc.identifier.doi | 10.3109/0284186X.2014.933874 | en_US |
dc.description.pages | 1305-11 | en |
dc.relation.url | https://pubmed.ncbi.nlm.nih.gov/24980044 | en |
dc.type.content | Text | en_US |
dc.type.austin | Journal Article | en |
local.name.researcher | Wada, Morikatsu | |
item.languageiso639-1 | en | - |
item.fulltext | No Fulltext | - |
item.grantfulltext | none | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.cerifentitytype | Publications | - |
item.openairetype | Journal Article | - |
crisitem.author.dept | Radiation Oncology | - |
crisitem.author.dept | Olivia Newton-John Cancer Wellness and Research Centre | - |
Appears in Collections: | Journal articles |
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.